HKEX: 1177
Voluntary announcement - enter into strategic biosimilars partnership with stada
View original source (HKEXnews)
Earlier from Sino Biopharmaceutical
- Sino Biopharmaceutical Limited Unveils New Global Brand, SBP Group, to Accelerate International Expansion
- Sino Biopharmaceutical: Once-Yearly Dosing, Targeting Cardiovascular Disorders, First US Patient Enrolled in China-US Phase II Clinical Trial of Hygieia's Kylo-11
- Sino Biopharm Releases 2025 Annual Results: Revenue and Net Profit Maintain Double-Digit Growth, Innovative Product Revenue Exceeds RMB 15 Billion
- Sino Biopharmaceutical: Positive on Dual Endpoints! CTTQ Pharma's Phase III Study of TQB3454 in Bile Duct Cancer Succeeds, Marketing Application to be Submitted